Physician profile
Beata Kwiatkowska
NPI 1427419316
$597,926.62
in general payments reported to CMS, 2019-2025
25 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Clinical Pathology/Laboratory Medicine providers received nationally (typical 2025 total: $114).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $71K · 2021: $66K · 2022: $75K · 2023: $95K · 2024: $118K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $336K · Royalty Or License: $6,000 · Food and Beverage: $1,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $335,659.50 |
| Royalty Or License | $6,000.00 |
| Food and Beverage | $1,916.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $325,159.50 | 2023-2025 | |
| Csl Behring | $268,363.79 | 2019-2024 | |
| Amgen INC. | $474.85 | 2019-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $365.37 | 2019-2025 | Libtayo |
| Akcea Therapeutics, INC. | $287.18 | 2019 | |
| Ucb, INC. | $250.00 | 2023-2024 | |
| Gilead Sciences, INC. | $242.20 | 2019-2023 | Veklury |
| Lucid Diagnostics INC. | $240.73 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $235.24 | 2023-2024 | Saphnelo, Ultomiris |
| Novo Nordisk INC | $231.00 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $224.09 | 2024 | Strensiq, Ultomiris |
| Biogen, INC. | $219.28 | 2019-2022 | |
| Lilly USA, LLC | $183.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $145.86 | 2024 | Sotyktu |
| Genentech, INC. | $129.24 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.97 | 2022 | |
| Radius Health, INC. | $124.95 | 2019 | |
| Genzyme Corporation | $123.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.06 | 2022 | |
| Kyowa Kirin, INC. | $119.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $119.22 | 2019 | |
| Abbvie INC. | $114.66 | 2023 | |
| Pfizer INC. | $114.55 | 2019 | |
| Celgene Corporation | $110.25 | 2019 | |
| Glaxosmithkline, LLC. | $104.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Kwiatkowska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.